We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long‐term low‐dose cabergoline usage: Another association with cardiac valvulopathy.
- Authors
Tessier, Steven; Lipton, Brooke A.; Arastu, Mohammad I.; Curiale, Andrew M.; Longo, Santo; Nanda, Sudip
- Abstract
A 60‐year‐old patient, professor of physics, presented in 1999 with sudden‐onset vitiligo associated with hyperprolactinemia and a prolactinoma. Fearful of potential surgical complications at the peak of his career, the patient declined surgery and opted for medical management with bromocriptine. The decreasing effectiveness of bromocriptine after 5 years required a switch to cabergoline. After a 15‐year‐course of cabergoline therapy with a cumulative dose of 572 mg, echocardiographic monitoring demonstrated aortic and mitral valve thickening and regurgitation. An additional 3 years of cabergoline treatment (cumulative dose: 649 mg) resulted in worsening valve thickening and regurgitation. It is well‐recognized that such valvular changes may occur with high‐dose cabergoline treatment. We report a case of mitral and aortic vavulopathy in a patient who was treated with long‐term (18 years) low‐dosage (.5–1 mg weekly) cabergoline. cabergoline, echocardiography, valvulopathy
- Subjects
DOPAMINE agonists; MITRAL valve diseases; ECHOCARDIOGRAPHY; MITRAL valve insufficiency; PITUITARY diseases; PROLACTINOMA; TREATMENT duration; ERGOT alkaloids; DOSE-effect relationship in pharmacology; AORTIC valve insufficiency; VITILIGO; AORTIC valve diseases
- Publication
Echocardiography, 2023, Vol 40, Issue 1, p61
- ISSN
0742-2822
- Publication type
Article
- DOI
10.1111/echo.15506